论文部分内容阅读
目的探讨胺碘酮治疗充血性心力衰竭并室性心律失常的疗效及安全性。方法将符合条件的160例充血性心力衰竭并室性心律失常患者随机分为治疗组及对照组,对照组给予常规抗心力衰竭加倍他乐克治疗,治疗组在常规治疗的基础上加胺碘酮治疗,对比分析两组患者在抗室性心律失常、左室射血分数、心脏性猝死、心力衰竭再住院率、药物不良反应等方面的情况。结果治疗组心功能改善和抗心律失常疗效优于对照组,再入院率和病死率低于对照组,差异有显著性(P<0.05),两组的不良反应无差异性(P>0.05)。结论胺碘酮治疗充血性心力衰竭合并室性心律失常安全、有效,不良反应轻。
Objective To investigate the efficacy and safety of amiodarone in the treatment of congestive heart failure and ventricular arrhythmia. Methods A total of 160 congestive heart failure and ventricular arrhythmia patients were randomly divided into treatment group and control group. The control group was given routine anti-heart failure and metoprolol treatment. The treatment group was treated with amine iodine Ketone therapy, comparative analysis of two groups of patients in the anti-ventricular arrhythmia, left ventricular ejection fraction, sudden cardiac death, heart failure rehospitalization rate, adverse drug reactions and so on. Results The improvement of cardiac function and antiarrhythmic effect in the treatment group were better than those in the control group, and the readmission rate and mortality were lower than those in the control group (P <0.05). There was no difference in adverse reactions between the two groups (P> 0.05) . Conclusions Amiodarone is safe and effective in treating congestive heart failure complicated with ventricular arrhythmia, with mild adverse reactions.